Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells take aim at Hard-to-Treat cancers

NCT ID NCT07297160

First seen Jan 04, 2026 · Last updated Apr 30, 2026 · Updated 18 times

Summary

This early-phase study tests a new gene therapy that trains a patient's own immune cells (T cells) to recognize and attack cancer cells carrying a protein called CD70. It is for people with lymphoma, myeloma, or certain solid tumors (like kidney cancer or sarcoma) that have returned or not responded to standard treatments. The main goals are to find a safe dose and understand side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

  • The Methodist Hospital

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.